TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06588621

Intervention type: OTHER
Intervention: Questionnaire on physical and mental health among healthcare professionnals
Description: Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting
Study: NCT06596993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMU-based balance training
Description: Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training

Intervention type: OTHER
Group type: OTHER
Intervention: general health education or exercise training
Description: general health education or exercise training
Study: NCT06589011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: spontaneously assisted breathing
Description: The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
Study: NCT06600009

Intervention type: DRUG
Intervention: Secukinumab
Description: Patients had received secukinumab per their dosing regimens prior to this observational study.

Intervention type: DRUG
Intervention: Adalimumab
Description: Patients had received adalimumab per their dosing regimens prior to this observational study.
Study: NCT06587451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPB898 (Induction and Maintenance)
Description: Induction and Maintenance: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo-EU (Induction)
Description: Induction: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo-US (Induction)
Description: Induction: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yervoy-EU (Induction)
Description: Induction: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yervoy-EU (Induction)
Description: Induction: Intravenous (IV)
Study: NCT06126731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40mg
Description: Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 400mg
Description: Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 125mg
Description: Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500g
Description: White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side
Study: NCT05900687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of mHealth Question Prompt List app
Description: mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
Study: NCT06587451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yervoy-EU (Induction)
Description: Induction: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo-EU (Maintenance)
Description: Maintenance: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo-EU (Maintenance)
Description: Maintenance: Intravenous (IV)
Study: NCT06590168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket Preservation by vestibular socket therapy
Description: Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Preservation by icecream cone technique
Description: Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
Study: NCT06589401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INP12
Description: Oral paclitaxel
Study: NCT06588374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral internal sphincterotomy
Description: Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral internal sphincterotomy
Description: Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
Study: NCT06598748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Interface Mobilisation Technique
Description: In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26).
Study: NCT05983757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion
Description: The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical management
Description: All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
Study: NCT06591520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112, Gemcitabine, Cisplatin
Description: AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab, Gemcitabine, Cisplatin
Description: Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
Study: NCT06588465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low dose On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low dose On-venous Laser Irradiation of Blood
Description: The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
Study: NCT06592573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT_ONLINE
Description: 10-12 sessions of cognitive behavioural therapy conducted online

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT_IN PERSON
Description: 10-12 sessions of cognitive behavioural therapy conducted in-person.
Study: NCT06603662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Subjects assigned to the Intervention A group will receive oral prednisone 50 mg once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Subjects assigned to the Intervention B group will receive a single oral dose of dexamethasone 10 mg, plus standard ibuprofen 600 mg every 8 hours for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
Study: NCT05525104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)
Description: This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration
Study: NCT06603948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral Focused Imaging
Description: Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White Light Imaging
Description: Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
Study: NCT06587841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)
Description: The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)
Description: The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
Study: NCT06588075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow
Description: All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol
Description: For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
Study: NCT06595836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Lubricated Synthetic polyisoprine condom
Description: Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Lubricated Natural Rubber Latex Condom
Description: Natural rubber latex condoms are made from natural rubber
Study: NCT06604507

Intervention type: DEVICE
Intervention: non-pharmacological app
Description: Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
Study: NCT06587061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.
Study: NCT06595498

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)
Description: The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cobas® EGFR Mutation Test v2 (Roche)
Description: The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
Study: NCT06604377

Intervention type: OTHER
Intervention: Observe
Description: Ruijin
Study: NCT06597604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative use of TenaTac in lung surgery
Description: Use of innovative medical device : TenaTac

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative use of usual sealant in lung surgery
Description: Use of the usual scealant as a control
Study: NCT06595667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse pressure variation
Description: Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous pressure
Description: Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
Study: NCT06599385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion if platelet count ≤ 10 G/L
Description: Platelet transfusion as soon as platelet count falls ≤ 10 G/L

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet transfusion when platelet count ≤ 20 G/L
Description: Platelet transfusion will be initiated immediately after randomisation
Study: NCT06587971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard periodontal treatment protocol
Description: Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.
Study: NCT05054153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined carbohydrate breakfast
Description: After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain breakfast
Description: After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
Study: NCT05712473

Intervention type: DIAGNOSTIC_TEST
Intervention: PYLARIFY
Description: PYLARIFY PET

Intervention type: DIAGNOSTIC_TEST
Intervention: PYLARIFY
Description: PYLARIFY PET
Study: NCT05550701

Intervention type: OTHER
Intervention: lymph node yield
Description: We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer

Intervention type: OTHER
Intervention: lymph node yield
Description: We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer